Progression-free survival as a clinical trial endpoint in advanced renal cell carcinoma

Current Oncology

Volumn 18, Issue SUPPL. 2, 2011, Pages

  Hotte, S J ^a   Bjarnason, G A ^b   Heng, D Y C ^c   Jewett, M A S ^d   Kapoor, A ^a   Kollmannsberger, C ^e   Maroun, J ^f   Mayhew, L A ^g   North, S ^h   Reaume, M N ⁱ   Ruether, J D ^c   Soulieres, D ^j   Venner, P M ^k   Winquist, E W ^l   Wood, L ^m   Yong, J H E ^m   Saad, F ^j  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

^f OTTAWA REGIONAL CANCER CENTRE   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h CROSS CANCER INSTITUTE   (Canada)

ⁱ UNIVERSITY OF OTTAWA   (Canada)

^j CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^k UNIVERSITY OF WESTERN ONTARIO   (Canada)

^l QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^m ST MICHAEL'S HOSPITAL   (Canada)

more..

Author keywords

Clinical trial endpoints; Kidney cancer; Overall survival; Progression free survival; Regulatory approval

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; PLACEBO; SORAFENIB; SUNITINIB; TEMSIROLIMUS;

ARTICLE; CANCER MORTALITY; DRUG EFFICACY; FOLLOW UP; HUMAN; KIDNEY CARCINOMA; LIFE EXPECTANCY; METASTASIS POTENTIAL; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROGNOSIS; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; STANDARD;

EID: 80053523278     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v18i0.941     Document Type: Article

References (28)

1. Rini BI, Halabi S, Rosenberg JE, et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: calgb 90206. J Clin Oncol 2008;26:5422-8.
2. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356:115-24.
3. Buyse M, Burzykowski T, Carroll K, et al. Progression-free survival is a surrogate for survival in advanced colorectal cancer. J Clin Oncol 2007;25:5218-24.
4. Amato RJ. Chemotherapy for renal cell carcinoma. Semin Oncol 2000;27:177-86.
5. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368-80.
6. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase iii trial. Lancet 2007;370:2103-11.
7. Escudier BJ, Bellmunt J, Negrier S, et al. Final results of the phase iii, randomized, double-blind avoren trial of first-line bevacizumab (bev) + interferon-a2a (ifn) in metastatic renal cell carcinoma (mrcc) [abstract 5020]. J Clin Oncol 2009;27:. [Available online at: /http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=32687; cited August 21, 2011]
8. Rini BI, Halabi S, Rosenberg J, et al. Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: results of overall survival for CALGB 90206 [abstract LBA5019]. J Clin Oncol 2009;27:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30922; cited August 21, 2011]
9. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cell cancer. N Engl J Med 2003;349:427-34.
10. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase iii trial. Lancet 2008;372:449-56.
11. Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase iii trial. J Clin Oncol 2010;28:1061-8.
12. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356:125-34.
13. Szczylik C, Demkow T, Staehler M, et al. Randomized phase ii trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results [abstract 5025]. J Clin Oncol 2007;25:. [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=47&abstractID=34559; cited August 21, 2011]
14. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
15. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 1989;8:431-40.
16. Health Canada. Record of Proceedings: February 26, 2009, Scientific Advisory Committee on Oncology Therapies (sacot) [Web page]. Ottawa, ON: Health Canada; 2009. [Available at: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/activit/sci-com/onco/sacot_rop_ccsto_ai_2009-02-26-eng.php; cited: August 21, 2011]
17. Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 2009;115:776-83.
18. Warren M, Venner PM, North S, et al. A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment. Can Urol Assoc J 2009;3:281-9.
19. Delea TE, Khuu A, Kay A, Zheng J, Baladi JF. Association between treatment effects on disease progression (dp) endpoints and overall survival (os) in patients with metastatic renal cell carcinoma (mrcc) [abstract 5105]. J Clin Oncol 2009; 27: [Available online at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstract ID=35312; cited August 21, 2011]
20. Heng DY, Xie W, Bjarnason GA, et al. Progression-free survival as a predictor of overall su0rvival in metastatic renal cell carcinoma treated with contemporary targeted therapy. Cancer 2011;117:2637-42.
21. Gill S, Berry S, Biagi J, et al. Progression-free survival as a primary endpoint in clinical trials of metastatic colorectal cancer. Curr Oncol 2011;18(suppl 2): S5-10.
22. Tang PA, Bentzen SM, Chen EX, Siu LL. Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy. J Clin Oncol 2007;25:4562-8.
23. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ. Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 2009;27:2766-71.
24. Burzykowski T, Buyse M, Piccart-Gebhart MJ, et al. Evaluation of tumor response, disease control, progressionfree survival, and time to progression as potential surrogate end points in metastatic breast cancer. J Clin Oncol 2008;26:1987-92.
25. Burzykowski T. Surrogate endpoints: wishful thinking or reality. Stat Methods Med Res 2008;17:463-6.
26. U.S. Department of Health and Human Services, Food and Drug Administration (fda). Guidance for Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. Washington, DC: fda; 2007.
27. European Medicines Agency (ema), Committee for Medicinal Products for Human Use. Guideline on the Evaluation of Anticancer Medicinal Products in Man. London, U.K.: ema; 2006.
28. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43.